Ftorafur hard capsules 400 mg. №100 vial

Description

Ftorafur Storage
active substance: tegafurum;

1 hard capsule contains 400 mg of tegafur;

excipient: stearic acid;

capsule:

body: quinoline yellow (E 104), iron oxide red (E 172), titanium dioxide (E 171), gelatin;

lid: crimson 4R (E 124), quinoline yellow (E 104), titanium dioxide (E 171), gelatin.

Ftorafur Dosage form
Hard capsules.

Main physical and chemical properties: hard gelatin capsules. The body of the capsules is yellow, the lid is orange. The content of the capsules is a white powder.

Ftorafur Pharmacotherapeutic group
Antineoplastic agents. Antimetabolites. Pyrimidine analogues.

ATX code L01B C03.

Pharmacological properties

Pharmacodynamics.

Tegafur and its sodium salt have antitumor effects and biologically resemble 5-fluorouracil. Tegafur can be considered as a transport form of 5-fluorouracil, which is formed in the body due to the activation of tegafur by microsomal liver enzymes. The metabolite circulates in the body for a long time, thus ensuring high efficiency of the drug.

During the metabolism of 5-fluorouracil, 5-fluoro-2′-deoxyuridine-5′-monophosphate is formed, which significantly reduces the activity of thymidyl synthetase. Under such conditions, a deficiency of thymidine-5′-monophosphate [which can be considered a specific precursor of deoxyribonucleic acid (DNA)] is formed, which stops the process of cell division, including malignant. In addition, another metabolite of 5-fluorouracil-5-fluorouridine-5′-triphosphate is included in the ribonucleic acid (RNA) chain and replaces uracil, which is also accompanied by RNA disorders. Tegafur causes more severe disturbances in biosynthesis than 5-fluorouracil. This indicates that tegafur acts not only as a transport form of 5-fluorouracil, but also independently. At the heart of the cytostatic effect of tegafur is its ability to interfere with the RNA metabolism of tumor cells (with small proliferation), which grow slowly. Such tumors include adenocarcinomas of the digestive tract.

Indication
Cancer of the colon and rectum, stomach, breast, cervical cancer, cutaneous lymphoma.

Contraindication
Hypersensitivity to the components of the drug;
established complete deficiency of dihydropyrimidine dehydrogenase (DPD) (see section “Features”);
terminal stage of the disease;
acute profuse bleeding;
severe functional disorders of the liver and / or kidneys;
leukopenia (less than 3 × 109 / l), thrombocytopenia (less than 100 × 109 / l) and anemia (hemoglobin level less than 30 units);
recent brivudine treatment or concomitant brivudine administration (see sections “Special warnings and special precautions for use” and “Interaction with other medicinal products and other forms of interaction”).